Search

Your search keyword '"Cardillo, Anna"' showing total 46 results
Start Over Author "Cardillo, Anna"
46 results on '"Cardillo, Anna"'

4. Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines

Author

Munzone, Elisabetta, Bagnardi, Vincenzo, Campennì, Giuseppe, Mazzocco, Ketti, Pagan, Eleonora, Tramacere, Andrea, Masiero, Marianna, Iorfida, Monica, Mazza, Manuelita, Montagna, Emilia, Cancello, Giuseppe, Bianco, Nadia, Palazzo, Antonella, Cardillo, Anna, Dellapasqua, Silvia, Sangalli, Claudia, Pettini, Greta, Pravettoni, Gabriella, Colleoni, Marco, and Veronesi, Paolo

Published
2019
Full Text
View/download PDF

6. European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance

Author

Munck, Anne, primary, Berger, Daria O, additional, Southern, Kevin W, additional, Carducci, Carla, additional, de Winter-de Groot, Karin M, additional, Gartner, Silvia, additional, Kashirskaya, Nataliya, additional, Linnane, Barry, additional, Proesmans, Marijke, additional, Sands, Dorota, additional, Sommerburg, Olaf, additional, Castellani, Carlo, additional, Barben, Jürg, additional, Renner, Sabine, additional, Zeyda, Max, additional, de Wachter, Elke, additional, Regal, Luc, additional, Votava, Felix, additional, Holubova, Andrea, additional, Skov, Marianne, additional, Morgan, Tessa, additional, Bregeaut, Paul, additional, O'Grady, Loretta, additional, Bucci, Ines, additional, Pantano, Stefano, additional, Simonetti, Simonetta, additional, De Venuto, Domenica, additional, Salvatore, Donatello, additional, Perrotti, Nicola, additional, Caloiero, Mimma, additional, Castaldo, Giuseppe, additional, Tosco, Antonella, additional, Righetti, Francesca, additional, Pisi, Giovanna, additional, Battistini, Fiorella, additional, Angeloni, Antonio, additional, Cimino, Giuseppe, additional, Fiocchi, Giovanni, additional, Angiolillo, Antonella, additional, Cassanello, Michela, additional, Alberti, Luisella, additional, Claut, Laura E, additional, Badolato, Raffaele, additional, Pavanello, Enza, additional, Fabrizzi, Benedetta, additional, Bignamini, Elisabetta, additional, Cardillo, Anna, additional, Lombardo, Mariangela, additional, Cocciadiferro, Letizia, additional, Termini, Lisa, additional, Dolce, Daniela, additional, Terlizzi, Vito, additional, Tamanini, Anna, additional, Pauro, Francesca, additional, la Marca, Giancarlo, additional, Aleksejeva, Elina, additional, Gaidule-Logina, Dita, additional, Fustik, Stoika, additional, Anastasovska, Violeta, additional, Bouva, Marelle, additional, Reid, Alastair, additional, Cundick, Jennifer, additional, Lundman, Emma, additional, Bakkeheim, Egil, additional, Zybert, Katarzyna, additional, Oltarzewski, Mariusz, additional, Vilarinho, Laura, additional, Sherman, Victoria, additional, Kondratyeva, Elena, additional, Smith, Sarah, additional, Dautovic, Gordana Vilotijevic, additional, Knapkova, Maria, additional, Mydlova, Zuzana, additional, López, Rosa Mª, additional, Velasco, Valle, additional, Flores, Felicitas Díaz, additional, Mejeras, Cristóbal Colón, additional, Pedersen, Eva SL, additional, Ozcelik, Ugur, additional, Karadag, Bulent, additional, Makukh, Halyna, additional, and Stuart, Moat, additional

Published
2023
Full Text
View/download PDF

11. How to Perform Repeat Sentinel Node Biopsy Safely After a Previous Mastectomy: Technical Features and Oncologic Outcomes

Author

Vicini, E, Leonardi, M, Fontana, S, Pagan, E, Bagnardi, V, Gilardi, L, Cardillo, A, Rafaniello Raviele, P, Sargenti, M, Morigi, C, Intra, M, Veronesi, P, Galimberti, V, Vicini, Elisa, Leonardi, Maria Cristina, Fontana, Sabrina Kahler Ribeiro, Pagan, Eleonora, Bagnardi, Vincenzo, Gilardi, Laura, Cardillo, Anna, Rafaniello Raviele, Paola, Sargenti, Manuela, Morigi, Consuelo, Intra, Mattia, Veronesi, Paolo, Galimberti, Viviana, Vicini, E, Leonardi, M, Fontana, S, Pagan, E, Bagnardi, V, Gilardi, L, Cardillo, A, Rafaniello Raviele, P, Sargenti, M, Morigi, C, Intra, M, Veronesi, P, Galimberti, V, Vicini, Elisa, Leonardi, Maria Cristina, Fontana, Sabrina Kahler Ribeiro, Pagan, Eleonora, Bagnardi, Vincenzo, Gilardi, Laura, Cardillo, Anna, Rafaniello Raviele, Paola, Sargenti, Manuela, Morigi, Consuelo, Intra, Mattia, Veronesi, Paolo, and Galimberti, Viviana

Abstract

Background: The latest National Comprehensive Cancer Network Breast Cancer Guidelines still discourage repeat sentinel node biopsy (SNB) after mastectomy, and the largest multicentric study available reports only 35 cases in the absence of previous axillary dissection (AD). Methods: From January 2003 to November 2018, 89 patients of the European Institute of Oncology with local recurrence of breast cancer after mastectomy, free of distant metastases, with a clinically negative axilla and a negative axillary ultrasound, in absence of AD, underwent lymphatic mapping before wide local excision. Results: During surgery, SNB was successful for 99% of the patients, with 14% being metastatic. Additional metastatic nodes removed by AD after a positive sentinel node occurred in 82% of cases. After a medium follow-up period of 3.7 years, the overall survival rate was 96.7%, and the disease-free survival rate was 84.4%. No axillary relapse after AD was recorded. One patient who refused human epidermal growth factor receptor 2 (HER2)-targeted treatment experienced ipsilateral axillary recurrence after a negative repeat SNB. The first axillary level was never directly irradiated because all the patients with positive repeat SNB underwent AD. For invasive luminal-like HER2-negative recurrences, the metastatic sentinel node was significantly associated with the choice to prescribe adjuvant chemotherapy (p = 0.003). Conclusions: In specialized centers, repeat axillary SNB for patients with local recurrence after mastectomy in the absence of previous AD can represent a safe option for detection and removal of occult axillary disease that would otherwise not be excised/irradiated to achieve better local control and could possibly influence the choice of adjuvant treatments.

Published
2022

14. Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial

Author

Dellapasqua, Silvia, primary, Trillo Aliaga, Pamela, additional, Munzone, Elisabetta, additional, Bagnardi, Vincenzo, additional, Pagan, Eleonora, additional, Montagna, Emilia, additional, Cancello, Giuseppe, additional, Ghisini, Raffaella, additional, Sangalli, Claudia, additional, Negri, Mara, additional, Mazza, Manuelita, additional, Iorfida, Monica, additional, Cardillo, Anna, additional, Sciandivasci, Angela, additional, Bianco, Nadia, additional, De Maio, Ana Paula, additional, Milano, Monica, additional, Campennì, Giuseppe Maria, additional, Sansonno, Loredana, additional, Viale, Giuseppe, additional, Morra, Anna, additional, Leonardi, Maria Cristina, additional, Galimberti, Viviana, additional, Veronesi, Paolo, additional, and Colleoni, Marco, additional

Published
2021
Full Text
View/download PDF

15. ASO Visual Abstract: How to Safely Perform Repeat Sentinel Node Biopsy After a Previous Mastectomy—Technical Features and Oncological Outcomes

Author

Vicini, Elisa, primary, Leonardi, Maria Cristina, additional, Fontana, Sabrina Kahler Ribeiro, additional, Pagan, Eleonora, additional, Bagnardi, Vincenzo, additional, Gilardi, Laura, additional, Cardillo, Anna, additional, Rafaniello Raviele, Paola, additional, Sargenti, Manuela, additional, Morigi, Consuelo, additional, Intra, Mattia, additional, Veronesi, Paolo, additional, and Galimberti, Viviana, additional

Published
2021
Full Text
View/download PDF

16. How to Perform Repeat Sentinel Node Biopsy Safely After a Previous Mastectomy: Technical Features and Oncologic Outcomes

Author

Vicini, Elisa, primary, Leonardi, Maria Cristina, additional, Fontana, Sabrina Kahler Ribeiro, additional, Pagan, Eleonora, additional, Bagnardi, Vincenzo, additional, Gilardi, Laura, additional, Cardillo, Anna, additional, Rafaniello Raviele, Paola, additional, Sargenti, Manuela, additional, Morigi, Consuelo, additional, Intra, Mattia, additional, Veronesi, Paolo, additional, and Galimberti, Viviana, additional

Published
2021
Full Text
View/download PDF

20. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features

Author

Montagna, Emilia, Bagnardi, Vincenzo, Rotmensz, Nicole, Viale, Giuseppe, Pruneri, Giancarlo, Veronesi, Paolo, Cancello, Giuseppe, Balduzzi, Alessandra, Dellapasqua, Silvia, Cardillo, Anna, Luini, Alberto, Zurrida, Stefano, Gentilini, Oreste, Mastropasqua, Mauro Giuseppe, Bottiglieri, Luca, Iorfida, Monica, Goldhirsch, Aron, and Colleoni, Marco

Published
2010
Full Text
View/download PDF

27. Abstract P2-14-18: Caelyx® as adjuvant treatment in early stage luminal B breast cancer: A feasibility phase II trial

Author

Dellapasqua, Silvia, primary, Bagnardi, Vincenzo, additional, Cancello, Giuseppe, additional, Sangalli, Claudia, additional, Pagan, Eleonora, additional, Mazza, Manuelita, additional, Iorfida, Monica, additional, Montagna, Emilia, additional, Cardillo, Anna, additional, Sciandivasci, Angela, additional, Bianco, Nadia, additional, De Maio, Ana Paula, additional, Milano, Monica, additional, Campennì, Giuseppe, additional, Sansonno, Loredana, additional, Negri, Mara, additional, and Munzone, Elisabetta, additional

Published
2020
Full Text
View/download PDF

30. Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines

Author

Munzone, E, Bagnardi, V, Campennì, G, Mazzocco, K, Pagan, E, Tramacere, A, Masiero, M, Iorfida, M, Mazza, M, Montagna, E, Cancello, G, Bianco, N, Palazzo, A, Cardillo, A, Dellapasqua, S, Sangalli, C, Pettini, G, Pravettoni, G, Colleoni, M, Veronesi, P, Munzone, Elisabetta, Bagnardi, Vincenzo, Campennì, Giuseppe, Mazzocco, Ketti, Pagan, Eleonora, Tramacere, Andrea, Masiero, Marianna, Iorfida, Monica, Mazza, Manuelita, Montagna, Emilia, Cancello, Giuseppe, Bianco, Nadia, Palazzo, Antonella, Cardillo, Anna, Dellapasqua, Silvia, Sangalli, Claudia, Pettini, Greta, Pravettoni, Gabriella, Colleoni, Marco, Veronesi, Paolo, Munzone, E, Bagnardi, V, Campennì, G, Mazzocco, K, Pagan, E, Tramacere, A, Masiero, M, Iorfida, M, Mazza, M, Montagna, E, Cancello, G, Bianco, N, Palazzo, A, Cardillo, A, Dellapasqua, S, Sangalli, C, Pettini, G, Pravettoni, G, Colleoni, M, Veronesi, P, Munzone, Elisabetta, Bagnardi, Vincenzo, Campennì, Giuseppe, Mazzocco, Ketti, Pagan, Eleonora, Tramacere, Andrea, Masiero, Marianna, Iorfida, Monica, Mazza, Manuelita, Montagna, Emilia, Cancello, Giuseppe, Bianco, Nadia, Palazzo, Antonella, Cardillo, Anna, Dellapasqua, Silvia, Sangalli, Claudia, Pettini, Greta, Pravettoni, Gabriella, Colleoni, Marco, and Veronesi, Paolo

Abstract

Background: Chemotherapy-induced alopecia (CIA) is a distressing side effect of cancer therapy. The trial aimed to assess feasibility and effectiveness of scalp-cooling system DigniCap® to prevent CIA in primary breast cancer patients receiving an anthracycline containing adjuvant chemotherapy (CT). Methods: Hair loss (HL) was evaluated by patient self-assessment and by the physician according to the Dean’s scale at baseline and after each cycle of CT. The primary efficacy endpoint was the patient self-assessment HL score evaluated at least 3 weeks after completing CT. A Dean's scale score of 0–2 (i.e. HL ≤50%) was considered a success. Results: From July 2014 to November 2016, 139 consecutive breast cancer patients were enrolled and received at least one treatment with scalp cooling. Fifty-six out of 131 evaluated patients successfully prevented HL (43%, 95% CI: 34–51%). Twenty-four patients (32%) discontinued the scalp cooling because of alopecia or scalp-cooling related AE, three patients had missing information on CIA, and 48 patients (64%) had a HL greater than 50% after CT. No serious AEs were reported. Conclusions: DigniCap® System resulted as a promising medical device to be safely integrated in supportive care of early breast cancer patients. Longer follow-up is needed to assess long-term safety and feasibility. Clinical trial registration number: NCT03712696.

Published
2019

31. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

Author

Orlando Laura, Cardillo Anna, Ghisini Raffaella, Rocca Andrea, Balduzzi Alessandra, Torrisi Rosalba, Peruzzotti Giulia, Goldhirsch Aron, Pietri Elisabetta, and Colleoni Marco

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background HER2/neu overexpression is linked to promotion of angiogenesis in breast cancer. We therefore tested the activity of the combination of Trastuzumab with metronomic, low dose chemotherapy with cyclophosphamide (CTX) and methotrexate (MTX) in metastatic breast cancer (MBC). Methods Between April 2002 and June 2005, twenty-two patients with metastatic breast cancer with the presence of overexpression or amplification of HER2-/neu, all pre-treated with trastuzumab plus other cytotoxics, were treated with trastuzumab (6 mg/kg every three weeks) in combination with metronomic chemotherapy (MTX 2.5 mg, bid on Day 1 and Day 4 every week) and CTX (50 mg daily) (CM). Results The 22 enrolled patients are evaluable: most had an ECOG performance status of 0 (17 pts), and all were pre-treated with chemotherapy for metastatic disease; 14 had progressive disease at study entry, and 11 had progressive disease during the last trastuzumab therapy. Metastatic sites included: lung (5 pts), liver (14 pts), bone (12 pts), lymph nodes (8 pts), central nervous system (CNS) (9 pts). We observed 4 partial remission (PR) (18%, 95% CI 5–40%), 10 stable disease (SD) (46%, 95% CI 24–68%), and 8 PD (36%, CI 17–59%). The clinical benefit (RP plus RC plus SD for ≥ 24 weeks) in all pts and in pts with disease resistant to previous trastuzumab therapy were 46% (95% CI, 24–68%) and 27% (95% CI, 6–61%), respectively. Median time to progression was 6 months and median duration of treatment was 5 months (range, 0,7 to 18.4 months and range, 1 to 18 months, respectively). Overall clinical toxicity was generally mild. Grade ≥2 reversible liver toxicity and leukopenia were reported in 5 and 3 pts, respectively. Conclusion The combination of trastuzumab and metronomic chemotherapy is effective and minimally toxic in advanced breast cancer patients. The efficacy observed in patients with disease resistant to trastuzumab supports the need of larger trial to confirm a role of this combination to delay acquired trastuzumab resistance.

Published
2006
Full Text
View/download PDF

32. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Author

Galimberti, Viviana, primary, Cole, Bernard F, additional, Viale, Giuseppe, additional, Veronesi, Paolo, additional, Vicini, Elisa, additional, Intra, Mattia, additional, Mazzarol, Giovanni, additional, Massarut, Samuele, additional, Zgajnar, Janez, additional, Taffurelli, Mario, additional, Littlejohn, David, additional, Knauer, Michael, additional, Tondini, Carlo, additional, Di Leo, Angelo, additional, Colleoni, Marco, additional, Regan, Meredith M, additional, Coates, Alan S, additional, Gelber, Richard D, additional, Goldhirsch, Aron, additional, Boyle, Fran, additional, Jerusalem, Guy, additional, Stahel, Rolf, additional, Aebi, Stefan, additional, Green, Michael, additional, Karlsson, Per, additional, Kössler, Ingrid, additional, Láng, Istvan, additional, Hiltbrunner, Anita, additional, Bernhard, Jürg, additional, Fournarakou, Stamatina, additional, Kammler, Roswitha, additional, Maibach, Rudolf, additional, Rabaglio, Manuela, additional, Ribi, Karin, additional, Roschitzki, Heidi, additional, Roux, Susanne, additional, Ruepp, Barbara, additional, Mahoney, Caitlin, additional, Price, Karen, additional, Blacher, Lynette, additional, Scolese, Tara, additional, Scott, Karolyn, additional, Lippert, Sandra, additional, Zielinski, Theresa, additional, Mastropasqua, Mauro, additional, Andrighetto, Stefania, additional, Dell'Orto, Patrizia, additional, Renne, Giuseppe, additional, Pruneri, Giancarlo, additional, Dellapasqua, Silvia, additional, Iorfida, Monica, additional, Cancello, Giuseppe, additional, Montagna, Emilia, additional, Cardillo, Anna, additional, Peruzzotti, Giulia, additional, Ghisini, Raffaella, additional, Luini, Alberto, additional, Veronesi, Umberto, additional, Gentilini, Oreste, additional, Zurrida, Stefano, additional, Curigliano, Giuseppe, additional, Nole, Franco, additional, Orecchia, Roberto, additional, Leonardi, Marisa Cristina, additional, Baratella, Paola, additional, Chifu, Camelia, additional, Sargenti, Manuela, additional, Crivellari, Diana, additional, Morassut, Sandro, additional, Mileto, Mario, additional, Piccoli, Erica, additional, Veronesi, Andreas, additional, Magri, Marisa Donatella, additional, Buonadonna, Angelo, additional, Candiani, Ezio, additional, Carbone, Antonino, additional, Perin, Tiziana, additional, Volpe, Rachele, additional, Roncadin, Mario, additional, Arcicasa, Mauro, additional, Coran, Francesco, additional, Lagrassa, Manuela, additional, Recalcati, Angelo, additional, Limonta, Maria Emanuela, additional, Tricomi, Paolo, additional, Fenaroli, Privato, additional, Candiago, Elisabetta, additional, Cattaneo, Laura, additional, Gianatti, Alberto, additional, Santini, Donatella, additional, Maweja, Sylvie, additional, Delvenne, Philippe, additional, Rorive, Andrée, additional, Collignon, Joëlle, additional, Garbay, Jean-Remi, additional, Mathieu, Marie-Christine, additional, Galatius, Hanne, additional, Hoffmann, Jack, additional, Schousen, Peer, additional, Lanng, Charlotte, additional, Hoerby, John, additional, Bruun Rasmussen, Birgitte, additional, Holtveg, Helle, additional, Moeller Talman, Maj-Lis, additional, Abugattas, Julio Elías, additional, Cotrina, Jose Manuel, additional, Dyer, Richard, additional, Lindtner, Jurij, additional, Majdic, Elga, additional, Frkovic-Grazio, Snjezana, additional, Oehlschlegel, Christian, additional, Ries, Gerhard, additional, Töpfer, Michael, additional, Lorenz, Ute, additional, Schiltknecht, Otto, additional, Späti, Bruno, additional, Ehrsam, Andreas, additional, Bamert, Monika, additional, Egli-Tupaj, Martina, additional, Rageth, Christoph, additional, Saurenmann, Elisabeth, additional, Tausch, Christoph, additional, Caduff, Rosmarie, additional, Moch, Holger, additional, Varga, Zsuzsanna, additional, Sarlos, Dimitri, additional, Kralidis, Elena, additional, Grobholz, Rainer, additional, Pagani, Olivia, additional, Bronz, Lucia, additional, Ghielmini, Michele, additional, Mazzucchelli, Luca, additional, Rusca, Tiziana, additional, Gyr, Thomas, additional, Leidi, Linda, additional, Caccia, Giorgio, additional, Wyss, Daniel, additional, Fey, Martin F., additional, Müller, Michael, additional, Günthert, Andreas, additional, Berclaz, Gilles, additional, Fleischmann, Achim, additional, Delaloye, Jean Francois, additional, Treboux, Assia, additional, Lehr, Hans-Anton, additional, Fiche, Maryse, additional, Perey, Lucien, additional, Zaman, Lucien, additional, Jeanneret Sozzi, Wendy, additional, Forbes, John, additional, Lindsay, D.F., additional, Preece, D.F., additional, Hill, Jane, additional, Jeal, P., additional, Smart, P., additional, Collins, John, additional, Mann, Gregory Bruce, additional, Millar, Robert, additional, Murphy, Craig, additional, Buchanan, Malcolm, additional, Murugasu, Anand, additional, French, James, additional, Elder, Elisabeth, additional, Mann, Lynette, additional, Moon, David, additional, Bilous, A. Michael, additional, Pathmanathan, Nirmala, additional, Howard, Virginia, additional, Gill, Petere G., additional, Kollias, James, additional, Bochner, Melissa, additional, Madigan, Linda, additional, Rippy, Elisabeth, additional, Whitfield, Robert, additional, Farshidi, Fereshte, additional, Moore, Katrina, additional, Sywak, Mark, additional, Tan, L., additional, Ross, William, additional, Briscoe, Karen, additional, Jones, Allison, additional, Shah, Aashit, additional, Lim, Elgene, additional, Macindoe, Robert, additional, Spillane, Andrew, additional, Bonar, S. Fiona, additional, Carmalt, Hugh, additional, West, Richard, additional, Mak, Cindy, additional, McKenzie, Paul, additional, Harman, Richard, additional, Gerred, Susanne, additional, Juhasz, Eva, additional, Allpress, Stephen, additional, Craik, Julie, additional, Campbell, Ian, additional, Chin, Paul, additional, Hayes, Lori, additional, Mayall, Frederick, additional, and Thorburn, M., additional

Published
2018
Full Text
View/download PDF

33. Critical Decisions for Older People With Advanced Dementia: A Prospective Study in Long-Term Institutions and District Home Care

Author

Franco Toscani, Jenny T. van der Steen, Silvia Finetti, Fabrizio Giunco, Francesca Pettenati, Daniele Villani, Massimo Monti, Simona Gentile, Lorena Charrier, Paola Di Giulio, Ventura Maurizio, Di Franco Gianni, Gandolfi Nicoletta, Saya Antonio, Mauro Anna, Colombetti Roberta, Pani Aldo, Cotticelli Claudio, Saba Lucia, Spotti Franco, Bacchi Giovanni, Gainotti Gianfranco, Belotti Gloria, Milesi Fiorenza, Rossi Borghesano Simona, Verando Emanuela, Migliorati Giuseppe, Premoli Monica, Manganelli Francesco, Caruso Marisa, Minuti Annalisa, Froldi Arnaldo, Chiesara Angelica, Subashi Blerina, Bellocchi Federica, D'Aquino Nicola, Giovinazzo Francesca, Bareggi Maria Chiara, Spertini Maria Teresa, Zucca Fabio, Grigis Maria, Conte Lorella, Panzera Tiziana, Cattaneo Carlo, Biason Antonella, Torchetti Maria Rosaria, Pelliccioli Irene, Di Maggio Maria Grazia, Villa Ivan, Monti Massimo, Gandelli Monica, Vignati Marco, Cutaia Chiara, Chiarella Gianna, Bellazzi Luca, Ribola Massimo, Rubini Elena, Raineri Chiara, Mainini Ermanna, Borsari Maria, Reggiani Alda, Balugani Paola, Buccella Milva, Cardillo Anna, Carillo Salvatore, Farinello Annalisa, Franchini Federica, Guidi Maria Grazia, Luise Luigi, Magnoni Elisa, Marchi Katia, Nava Letizia, Sabetta Anna, Sani Elena Sporziello Monica, Stermieri Lara, Martinelli Morena, Pirotti Mirco, Costi Adriana, Boni Manuela, Capedri Simonetta, Cavecchi Sonia, Dailari Nicoletta, Favali Enrica, Costoli Elena, Fossa Grazia, Mazzone Daniela, Patacini Paola, Ruozzi Gloria, Sironi Ornella, Murac Aurora, Trolla Lisa, Begotti Sabrina, Saba Andreina, Immovilli Maura, Ferrari Paola, Gabbi Monica, Saccani Maria, General practice, and EMGO - Quality of care

Subjects
Male, end of life, Pediatrics, medicine.medical_specialty, Palliative care, Decision Making, Comorbidity, Disease, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Interviews as Topic, Quality of life, medicine, Humans, Dementia, Prospective Studies, Medical prescription, Prospective cohort study, Geriatric Assessment, General Nursing, Aged, Demography, business.industry, Health Policy, General Medicine, critical decisions, medicine.disease, Home Care Services, Long-Term Care, Survival Analysis, end of life, advanced dementia, critical decisions, Italy, advanced dementia, Advanced dementia, Quality of Life, Female, Geriatrics and Gerontology, Nursing homes, business, Follow-Up Studies
Abstract

Item does not contain fulltext OBJECTIVE: To describe and compare the decisions critical for survival or quality of life [critical decisions (CDs)] made for patients with advanced dementia in nursing homes (NHs) and home care (HC) services. DESIGN: Prospective cohort study with a follow-up of 6 months. SETTING: Lombardy Region (NHs) and Reggio-Emilia and Modena Districts (HC), Italy. PARTICIPANTS: Patients (496 total; 315 in NHs and 181 in HC) with advanced dementia (Functional Assessment Staging Tool score >/= 7) and expected survival >/= 2 weeks. MEASUREMENTS: At baseline, the patients' demographic data, date of admission and of dementia diagnosis, type of dementia, main comorbidities, presence of pressure sores, ongoing treatments, and current prescriptions were abstracted from clinical records. At baseline and every 15 days thereafter, information regarding the patients' general condition and CDs (deemed critical by the doctor or team) was collected by an interview with the doctor. For each CD, the physician reported the problem that led to the decision, that was eventually made, the purpose of the decision, whether the decision had been discussed with and/or communicated to the family, who made the final decision, whether the decision was maintained after 1 week, whether it corresponded to what the doctor would have judged appropriate, and the expected survival of the patient (

Published
2015
Full Text
View/download PDF

35. A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer

Author

Colleoni, Marco, primary, Bagnardi, Vincenzo, additional, Rotmensz, Nicole, additional, Viale, Giuseppe, additional, Mastropasqua, Mauro, additional, Veronesi, Paolo, additional, Cardillo, Anna, additional, Torrisi, Rosalba, additional, Luini, Alberto, additional, and Goldhirsch, Aron, additional

Published
2010
Full Text
View/download PDF

36. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features

Author

Balduzzi, Alessandra, primary, Montagna, Emilia, additional, Bagnardi, Vincenzo, additional, Torrisi, Rosalba, additional, Bertolini, Francesco, additional, Mancuso, Patrizia, additional, Scarano, Eloise, additional, Viale, Giuseppe, additional, Veronesi, Paolo, additional, Cardillo, Anna, additional, Orlando, Laura, additional, Goldhirsch, Aron, additional, and Colleoni, Marco, additional

Published
2009
Full Text
View/download PDF

37. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

Author

Colleoni, Marco, primary, Bagnardi, Vincenzo, additional, Rotmensz, Nicole, additional, Gelber, Richard D., additional, Viale, Giuseppe, additional, Pruneri, Giancarlo, additional, Veronesi, Paolo, additional, Torrisi, Rosalba, additional, Cardillo, Anna, additional, Montagna, Emilia, additional, Campagnoli, Elisabetta, additional, Luini, Alberto, additional, Intra, Mattia, additional, Galimberti, Viviana, additional, Scarano, Eloise, additional, Peruzzotti, Giulia, additional, and Goldhirsch, Aron, additional

Published
2008
Full Text
View/download PDF

38. Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

Author

Viale, Giuseppe, primary, Rotmensz, Nicole, additional, Maisonneuve, Patrick, additional, Bottiglieri, Luca, additional, Montagna, Emilia, additional, Luini, Alberto, additional, Veronesi, Paolo, additional, Intra, Mattia, additional, Torrisi, Rosalba, additional, Cardillo, Anna, additional, Campagnoli, Elisabetta, additional, Goldhirsch, Aron, additional, and Colleoni, Marco, additional

Published
2008
Full Text
View/download PDF

39. HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17

Author

Torrisi, Rosalba, primary, Rotmensz, Nicole, additional, Bagnardi, Vincenzo, additional, Viale, Giuseppe, additional, Curto, Barbara Del, additional, Dell’Orto, Patrizia, additional, Veronesi, Paolo, additional, Luini, Alberto, additional, D’Alessandro, Claudia, additional, Cardillo, Anna, additional, Goldhirsch, Aron, additional, and Colleoni, Marco, additional

Published
2007
Full Text
View/download PDF

42. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.

Author

Montagna, Emilia, Bagnardi, Vincenzo, Rotmensz, Nicole, Viale, Giuseppe, Pruneri, Giancarlo, Veronesi, Paolo, Cancello, Giuseppe, Balduzzi, Alessandra, Dellapasqua, Silvia, Cardillo, Anna, Luini, Alberto, Zurrida, Stefano, Gentilini, Oreste, Mastropasqua, Mauro, Bottiglieri, Luca, Iorfida, Monica, Goldhirsch, Aron, and Colleoni, Marco

Abstract

In order to evaluate the outcome of patients with breast cancer according to response after primary therapy and according to clinical and biologic baseline features, we identified patients who were treated with preoperative therapy and who underwent surgery at the European Institute of Oncology (IEO), Milan, Italy, between 1995 and 2006. The outcome of patients who achieved pathological complete remission (pCR) and patients with residual disease (RD) at final surgery was analyzed. Of the 687 patients treated with preoperative therapy, we identified 82 patients who achieved pCR (12%) and 605 patients with RD (88%). A statistically significant difference in disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) was observed for patients with pCR compared with those who had RD (5 year DFS 73% vs. 59% P = 0.029; 5 year DDFS 81% vs. 72% P = 0.085; 5 year OS 88% vs. 77% P = 0.033). At the multivariate analysis, for patients achieving pCR, large tumor size (>5 cm) correlated with worse DFS (HR 3.18; 95% CI 1.34-7.51); clinical nodal involvement was associated with poorer DFS and DDFS (HR 6.94; 95% CI 1.62-29.73 and HR 9.87 95% CI 1.29-75.53, respectively). pCR after preoperative systemic therapy correlated with significant improved outcome. A substantial rate of relapse was observed for patients with large tumors and with clinical nodal involvement at baseline. Further improvement in adjuvant treatment might be warranted. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

43. Investigation of F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.

Author

Gilardi, Laura, De Cicco, Concetta, Colleoni, Marco, Cardillo, Anna, Montagna, Emilia, Dellapasqua, Silvia, Galimberti, Viviana, Bagnardi, Vincenzo, and Paganelli, Giovanni

Subjects
POSITRON emission tomography, CANCER patients, BREAST cancer treatment, CANCER invasiveness, DIAGNOSTIC imaging
Abstract

Purpose: The main objective of this study was to determine the role of [F]-2-fluoro-2-deoxy- D-glucose positron emission tomography (FDG PET) in the selection of patients with breast cancer as candidates for sentinel node biopsy (SNB) after neoadjuvant therapy. Methods: Forty-four patients with primary breast cancer clinically classified as cT2, cT3 or cT4 cN0-N2 or cN3 M0 and with a baseline FDG PET scan positive both in the site of primary tumour and axillary lymph nodes underwent neoadjuvant therapy and then a second FDG PET scan. In the case of axillary FDG PET uptake, patients underwent axillary lymph node dissection (ALND). If the second FDG PET scan was negative for axillary involvement, SNB was performed in order to evaluate axillary lymph node status. Only in the case of SN positivity did total ALND follow. Results: Specificity and positive predictive value of FDG PET for detection of axillary lymph node metastases after neoadjuvant therapy were as high as 83% (95% confidence interval: 51–97%) and 85% (95% confidence interval: 54–97%), respectively, whereas sensitivity, negative predictive value and diagnostic accuracy were inadequate for a correct staging (34, 32 and 48%, respectively). Conclusion: The poor sensitivity of FDG PET in detecting axillary lymph node metastases makes SNB mandatory in cases of a negative scan. The relatively high positive predictive value seems to suggest a role of FDG PET in selecting patients who, after neoadjuvant therapy, are candidates for ALND, avoiding SNB. However, this issue requires confirmation in a larger series of patients. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

44. Pegylated Liposomal Doxorubicin (Caelyx ® ) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial.

Author

Dellapasqua S, Trillo Aliaga P, Munzone E, Bagnardi V, Pagan E, Montagna E, Cancello G, Ghisini R, Sangalli C, Negri M, Mazza M, Iorfida M, Cardillo A, Sciandivasci A, Bianco N, De Maio AP, Milano M, Campennì GM, Sansonno L, Viale G, Morra A, Leonardi MC, Galimberti V, Veronesi P, and Colleoni M

Subjects
Doxorubicin analogs & derivatives, Feasibility Studies, Female, Humans, Middle Aged, Polyethylene Glycols, Breast Neoplasms drug therapy
Abstract

Background: Adjuvant chemotherapy for Luminal B-like breast cancers usually includes anthracycline-based regimens. However, some patients are reluctant to receive chemotherapy because of side-effects, especially alopecia, and ask for a "less intensive" or personalized approach., Patients and Methods: We conducted a phase II feasibility trial to evaluate pegylated liposomal doxorubicin (PLD, Caelyx ® ) as adjuvant chemotherapy. Patients who received surgery for pT1-3, any N, and luminal B-like early-stage breast cancer (EBC) candidates for adjuvant chemotherapy were included. PLD was administered intravenously at 20 mg/m 2 biweekly for eight courses. Endocrine therapy was given according to menopausal status. Trastuzumab was administered in HER2-positive disease. The primary endpoint was to evaluate the feasibility of this regimen, defined as the ability of a patient to achieve a relative dose intensity (RDI) of at least 85% of the eight cycles of treatment. Secondary endpoints included adverse events (AEs), tolerability, breast cancer-free survival, disease-free survival, and overall survival., Results: From March 2016 to July 2018, 63 patients were included in the trial. Median age was 49 years (range: 33-76), with mostly pre- and peri-menopausal (65%) and stage I-II (94%). Only 5% of patients had HER2-positive EBC. Median RDI was 100% (range: 12.5-100%; interquartile range, IQR: 87.5-100%). The proportion of patients meeting the primary endpoint was 84% (95% confidence interval, CI: 73-92%). Overall, 55 out of 63 enrolled patients completed treatment (87%, 95% CI: 77-94%). Most common AEs were palmar-plantar erythrodysesthesia (12.2%), fatigue (10.4%), and mucositis (8.5%). Only 13% of patients had G3 AEs. None had alopecia. After a median follow-up of 3.9 years (range: 0.3-4.7) two distant events were observed, and all patients were alive at the date of last visit., Conclusions: The trial successfully met its primary endpoint: the regimen was feasible and well tolerated and could be considered for further evaluation as a treatment option for patients with contraindications to standard anthracyclines or requiring a personalized, less intensive approach.

Published
2021
Full Text
View/download PDF

45. Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies.

Author

Bonmassar L, Fossile E, Scoppola A, Graziani G, Prete SP, Formica V, Cappelletti D, De Vecchis L, Cardillo A, Concolino F, D'Atri S, Balduzzi A, Torino F, Caporaso P, Greiner JW, Bonmassar E, Roselli M, and Aquino A

Subjects
Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal immunology, Antibodies, Monoclonal metabolism, Antimetabolites, Antineoplastic pharmacology, Carcinoembryonic Antigen metabolism, Cell Line, Tumor, Colonic Neoplasms immunology, Enzyme Inhibitors pharmacology, Female, Fluorouracil pharmacology, Humans, Immunoblotting, Immunomagnetic Separation, Keratin-19 metabolism, Male, Mice, Middle Aged, Neoplasm Metastasis, Neoplastic Cells, Circulating drug effects, Neoplastic Cells, Circulating metabolism, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Up-Regulation, Biomarkers, Tumor analysis, Carcinoembryonic Antigen genetics, Colonic Neoplasms blood, Keratin-19 genetics, Neoplastic Cells, Circulating pathology, Staurosporine pharmacology
Abstract

(51)Cr-prelabelled colon cancer cells (simulating 'circulating tumor cells', CTCs) were added to human peripheral blood and exposed to staurosporine (ST) to increase carcinoembryonic antigen (CEA) expression. CTCs were captured with immunomagnetic beads coated with Ber-EP4 monoclonal antibody, recognizing the common epithelial antigen present in the majority of cancer cells of epithelial origin, with capture efficiency of more than 80%. Moreover, ST treatment increased CEA expression without compromising Ber-EP4 capture efficiency. In a pilot clinical study on 37 patients, CTCs were captured using Ber-EP4 beads, and recognized by RT-PCR set for CEA or cytokeratin-19 (CK) mRNA detection. The results showed that: (a) the percentage of CEA-positive CTCs (CTC(CEA), 54.1%) was lower than that of CK-positive CTCs (CTC(CK), 70.3%); (b) in vitro ST treatment converted a significant number of CTC(CEA)-negative into CTC(CEA)-positive cases. Therefore, immunomagnetic capture combined with exposure to ST provides a feasible and sensitive technique for the detection of functionally-active CTCs responsive to ST-mediated CEA up-regulation.

Published
2010

46. Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro.

Author

Turriziani M, Di Giacomo AM, Cardillo A, Torino F, Tentori L, Nasuti P, Massara MC, Roselli M, Bonmassar E, and De Vecchis L

Subjects
Apoptosis, Biomarkers, Tumor analysis, Flow Cytometry, Humans, In Vitro Techniques, Jurkat Cells, Leukemia, T-Cell, Leukocytes, Mononuclear cytology, Leukocytes, Mononuclear drug effects, Phytohemagglutinins pharmacology, Reference Values, Tumor Cells, Cultured, Cell Survival radiation effects, Gamma Rays, Telomerase metabolism
Abstract

Background: Residual telomerase activity (TA) could be used as a marker of malignant or normal cell survival after exposure to cytotoxic agents. Therefore TA after treatment with ionizing radiation was used in a radiosensitivity assay., Materials and Methods: Radiosensitive MOLT-4 and relatively radioresistant Jurkat leukemia cells or normal peripheral blood mononuclear cells (MNC) were irradiated with 5-160 Gy. Cell count, MTT assay and telomerase activity were evaluated on day 3 and clonogenic assay on day 10., Results: In Jurkat cells, irradiation inhibited tumor growth and total TA per culture (TA/culture), but up-regulated TA per viable cell (TA/cell). TA/culture and TA/cell were profoundly depressed by irradiation of MOLT-4 or phytohemagglutinin-activated MNC., Conclusion: Susceptibility of normal or neoplastic cells to high-dose radiation can be monitored by evaluating residual TA/culture. In some cases, however, difficulties in the interpretation of the results could stem from radiation-induced increase of TA/cell, as observed for the Jurkat cell line.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results